Sugi Predict

Sugi Predict / Compounds / Adenosine

Adenosine

Adenosine

SCHEMBL3134331

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.O=P([O-])([O-])OP(=O)([O-])OP(=O)([O-])[O-].[K+].[K+].[K+].[K+].[K+]

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3

The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 known ✓ P30542 3/20 0.75
▸ ADORA3 known ✓ P0DMS8 1/20 0.75
▸ ADORA2A known ✓ P29274 1/20 0.75
▸ ADORA2B known ✓ P29275 1/20 0.75
▸ SMN1; SMN2 Q16637 3/20 0.75
▸ DPP4 P27487 1/20 0.75
▸ MEN1 O00255 1/20 0.75
▸ SLC28A1 O00337 1/20 0.75
▸ MAP3K7 O43318 1/20 0.75
▸ SLC28A2 O43868 1/20 0.75
▸ GAPDH P04406 1/20 0.75
▸ MAPK1 P28482 1/20 0.75
▸ STAT6 P42226 1/20 0.75
▸ PI4KA P42356 1/20 0.75
▸ KMT2A Q03164 1/20 0.75
▸ PI4K2B Q8TCG2 1/20 0.75
▸ DOT1L Q8TEK3 1/20 0.75
▸ SLC29A1 Q99808 1/20 0.75
▸ PI4K2A Q9BTU6 1/20 0.75
▸ SLC28A3 Q9HAS3 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine SCHEMBL7516483 1.00 ADORA1 (0.75) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
Adenosine SCHEMBL3332132 0.99 ADORA1 (0.74) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
Adenosine SCHEMBL3183004 0.99 ADORA1 (0.77) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
Adenosine SCHEMBL2442774 0.99 ADORA1 (0.77) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
Adenosine SCHEMBL3166848 0.98 ADORA1 (0.75) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
Adenosine SCHEMBL926532 0.98 ADORA1 (0.75) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
Adenosine SCHEMBL925631 0.98 ADORA1 (0.75) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
Adenosine SCHEMBL3343948 0.98 ADORA1 (0.75) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
Adenosine SCHEMBL924728 0.98 ADORA1 (0.75) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
Adenosine SCHEMBL10396858 0.97 ADORA1 (0.74) ADORA1SMN1; SMN2DPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161212-A1 LIQUID PHARMACEUTICAL FORMULATION OF OMEPRAZOLE OR ESOMEPRAZOLE ALKALOID AD SKOPJE (MK) 2025-05-22 — — US disclosed
WO-2025026441-A1 USE OF PROTON PUMP REGULATOR IN PREPARATION OF DRUG 上海魁特迪生物科技有限公司 2025-02-06 — — WO disclosed
WO-2025002400-A1 ATP6V1B2 BINDING AGENT AND USE THEREOF 上海魁特迪生物科技有限公司 2025-01-02 — — WO disclosed
EP-4458369-A1 USE OF PROTON PUMP MODULATOR IN PREPARING REAGENT Shanghai Quietd Biotechnology Co., Ltd. (CN) 2024-11-06 — — EP disclosed
US-20240343762-A1 USE OF PROTON PUMP MODULATOR IN PREPARING REAGENT SHANGHAI QUIETD BIOTECHNOLOGY CO., LTD. (CN) 2024-10-17 — — US disclosed
EP-3474836-B1 SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT REKIK RAOUF (TN) 2024-01-17 — — EP disclosed
EP-3965735-B1 PHARMACEUTICAL FORMULATION COMPRISING A BENZIMIDAZOLE ALKALOID AD SKOPJE (MK) 2023-08-30 — — EP disclosed
US-20230172918-A1 PHARMACEUTICAL FORMULATION ALKALOID AD SKOPJE (MK) 2023-06-08 — — US disclosed
US-11634545-B2 Layered-substance-containing solution and method of manufacturing same ADEKA CORPORATION (JP) 2023-04-25 — — US disclosed
CN-110088209-B Layered substance-containing liquid and method for producing same 株式会社ADEKA 2023-01-31 — — CN disclosed
US-20040009957-A1 Protective effects of PDE-5 inhibitors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-01-15 — — US disclosed
WO-2003101276-A2 PROTECTIVE EFFECTS OF PDE-5 INHIBITORS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2003-12-11 — — WO disclosed
CN-1422272-A Pyrrolopyridazine compound SANKYO CO (JP) 2003-06-04 — — CN disclosed
WO-2001030332-A3 METHODS OF PROTECTING NEURONAL FUNCTION UNIV WAKE FOREST (US) 2002-05-10 — — WO disclosed
US-6313112-B1 Methods of protecting neuronal function WAKE FOREST UNIVERSITY 2001-11-06 — — US disclosed
US-6313112-B1 Methods of protecting neuronal function WAKE FOREST UNIVERSITY 2001-11-06 — — US disclosed
WO-2001030332-A2 METHODS OF PROTECTING NEURONAL FUNCTION WAKE FOREST UNIVERSITY (US) 2001-05-03 — — WO disclosed
WO-2001030332-A2 METHODS OF PROTECTING NEURONAL FUNCTION WAKE FOREST UNIVERSITY (US) 2001-05-03 — — WO disclosed
CN-1044811-C Pyrrolopyridazine derivatives SANKYO CO (JP) 1999-08-25 — — CN disclosed
CN-1143964-A Pyrrolopyridazine derivative SANKYO CO (JP) 1997-02-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230172918-A1 PHARMACEUTICAL FORMULATION PGA5, HRH2, SI ADORA1 2417/4885ADORA3 2713/4885ADORA2A 2985/4885
US-20250161212-A1 LIQUID PHARMACEUTICAL FORMULATION OF OMEPRAZOLE OR ESOMEPRAZOLE PGA5, SI, ATP6AP1 ADORA1 2028/4885ADORA3 1906/4885ADORA2A 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.